About this trial
By using 16S rRNA sequencing technology to analyze the changes in ocular surface microbiota before and after surgery, as well as the impact of changes in ocular surface microbiota on FS-LASIK induced DES, new treatment ideas are provided for corneal FS-LASIK induced DES patients, and the incidence of FS-LASIK related DES is reduced.
Eligibility criteria
Qualifiers
Age ≥ 18 years old;
Stable refractive index (refractive index change less than 0.5D in the past 2 years);
The best corrected far vision (CDVA) is 1.0 or better;
Postoperative dry eye patients need to meet the following criteria: Patient's Eye Surface Disease Index (OSDI) ≥ 13 and two of the following three criteria are met: Tear film rupture time (BUT) ≤ 10S Schirmer I test (mm/5min) ≤ 10mm, corneal fluorescein sodium staining exceeding 5 spots;
Disqualifiers
History of eye trauma or surgery;
Suspected keratoconus;
Previously suffering from other eye diseases such as keratitis or edema, glaucoma, uveitis, retinal detachment, macular degeneration, cataracts, amblyopia, etc.;
Preoperative history of severe dry eye disease;
Trial design
Treatments tested in this trial
- Not listed